top of page

Revolutionizing Drug Discovery with AI-Driven Innovation

Accelerating Breakthroughs in Rare and Complex Diseases

Ryniant Sciences is dedicated to leveraging AI-driven innovation to accelerate breakthroughs in rare and complex diseases. Our Ominor Platform is at the forefront of drug discovery, revolutionizing the way treatments are developed.

Support Us

Support us in our various projects by donating to Ryniant Sciences, either as a collective or selecting specific focus areas (i.e. drug development or STEM). 

Gradient Background

Our Journey to inovation

Screenshot 2025-04-14 213528_edited_edited_edited.png

At Ryniant Sciences, our journey to innovation is driven by a relentless pursuit of groundbreaking discoveries in the fields of AI integrated therapeutics and health informatics development.

We are passionate about pushing the boundaries of science and technology to create impactful solutions that transform the landscape of healthcare. While engaging in democratization of the industry as a whole.

Recent News at Ryniant

Ominor Platform Development

A team of 3 has been assembled by the executive team as well as our professional Board of Advisors to develop the Ominor Platform. 
Learn more about the Ominor Platform 
Blue Abstract Structure

Our Innovations & Projects

Explore our innovative subsidiaries and breakthrough solutions that are shaping the future of healthcare.

NeuroLuma

Discover the innovative advancements in neurological treatments with NeuroLuma, designed to address complex neurological disorders and conditions.

RarusLuma

RarusLuma focuses on developing revolutionary treatments for rare diseases, offering hope to patients with unmet medical needs.

CutisLuma

Explore the pioneering treatments in dermatology and skincare with CutisLuma, redefining standards of care and efficacy.

ISSA Education Initiative

Our commitment to global science education is exemplified through the ISSA initiative, empowering the next generation of scientific leaders.

Thalos Biodefense

Thalos focuses on developing specialized AI tools to address biodefense concerns, offering a quicker and more efficient response to potential biowarfare attacks.

Gradient Background

Our Business Model

Ryniant Sciences operates multiple subsidiary companies. This approach is commonly referred to as the vant model of company development. Ryniant’s subsidiary model enhances efficiency by combining specialized research with a shared AI core. Each subsidiary focuses on a specific field while leveraging Ominor for drug discovery. This structure optimizes resources, accelerates breakthroughs, and scales innovations globally. 🚀

Advancing Healthcare Through Efficiency

AI-Driven Solutions

Rare Diseases

50%

drug development timeline cut

60%

drug development cost cut 

12

Industry & academic Experts backing

Gradient Background

Learn about our leadership & expert backing

Gradient Background
Four Purple Squares

Potential Impact

With our commitment to keeping our researched tools open access, we can significantly reduce barriers to entry for the drug development industry 

- Join us

Join our team and be on the forefront of development for novel tools for biotech democratization & innovation , public health improvement,  and health informatics. Contact us for opportunities. 

Contact Us

Gradient Background

Get Involved

Please go to the dedicated donations page to get more goal specific choices for donations. 

Contact Us

bottom of page